SlideShare una empresa de Scribd logo
1 de 39
Esophageal ESD




National Cancer Center Hospital, Tokyo
          Endoscopy Division
          Ichiro Oda, MD
Agenda



 Introduction

 Indication of Endoscopic resection for esophageal SCC

 ESD for esophageal SCC
Incidence and Mortality

Esophageal cancer
  It is the eighth most common cancer
   worldwide, accounting for 462,000 new cases in
   2002.
  It is the sixth most common cause of cancer
   related death (386,000 deaths).
  Squamous cell carcinoma (SCC) is the most
   common histological type worldwide.

 Japan
      Adenocarcinoma             1-2%
      SCC                        92-93%
      Others                    5-6%
                          Muto M, et al. J Clin Oncol 2010;28:1566-72.
Risk Factors for SCC in Esophagus


 Alcohol
 Smoking
 Male
 over 50ys
 History of Esophageal Cancer
 History of Head and Neck Cancer
 Family history
 Achalasia

Castellsague X, et al , Cancer 82:657-664,1999
Aggestrup S, et al. Chest 102:1013‐ 1016,1992
T. Yoshida , et al. The GI Forefront (Japanese Journal) vol3 (2) 118-122,2007
Risk Factors for SCC in Esophagus


 Prevalence of drinkers and smokers in Japanese
  men is so high.
     35.7% of men drink every day
     43.3% are current smokers in 2004

 Aldehyde dehydrogenase-2 (ALDH2) genotype
  determines an individual’s blood acetaldehyde
  concentration.

 Acetaldehyde has been established as a carcinogen in
  experimental animals and is also suspected of playing
  a critical role in cancer development in humans.

      Yokoyama T, et al. Cancer Epidemiol Biomarkers Prev 2008;17:2846-54.
Risk Factors for SCC in Esophagus

 Recent study shows that inactive ALDH2 is a very
  strong risk factor for esophageal SCC in alcohol
  drinkers.
 Alcohol flushing is a marker of inactive ALDH2.
         Yokoyama T, et al. Cancer Epidemiol Biomarkers Prev 2008;17:2846-54.
Agenda



 Introduction

 Indication of Endoscopic resection for esophageal SCC

ESD for esophageal SCC
Indications for endosopic resection




  Depth of tumor invasion


  Mucosal defect (luminal circumference)
Relationship Between Depth of Invasion and Lymph Node
       Metastasis in Superficial Esophageal Cancer


             m1      m2       m3       sm1       sm2      sm3
    EP
   LPM
   MM

   SM

                  Frequency of Lymph Node Metastasis

            0%       0%        10〜15%              40〜50%



         Definite Indication
                           Relative Indication
                                             Definite Non-indication
M2
SM2
Mucosal defect >3/4 luminal circumference




                                     Require
                                     balloon
                                     dilatation


Mucosal defect
>3/4 luminal
circumference
                 develop stenosis
Stenosis
                             Stenosis +ve Stenosis -ve
                                 n=11        n=54


                 < 1/2                  2                 40
Circumferental
               > 1/2                    4                 13
extention
                 > 3/4                  5                   1      < 0.0001



Longitudinal diameter (mm)    45.0±15.9 31.5±13.6 0.0062
Circumferental diameter (mm)   37.2±8.6 26.8±9.7 0.0020

                               Ono S, Fujishiro M, et al. Gastroint Endosc 2009
Agenda



 Introduction

 Indication of Endoscopic resection for esophageal SCC

ESD for esophageal SCC
Endoscopic resection modalities

 Endoscopic mucosal resection (EMR)
        Strip biopsy
        EMR with cap
        EMR with ligating device
        EEMR tube
        etc


  Endoscopic submucosal dissection (ESD)
EMR
Strip Biopsy                      EMR with a cap-fitted
                                  scope (EMRC)




       Tada M, et al. Endoscopy 1993   Inoue H et al. Gastrointest Endosc. 1993


• Technically simple
• Low en-bloc resection rate
• Difficult to resect large lesions
EMRC




SCC, m1, , 1cm, ly0, v0, cut end(-)
Piecemeal resection of EMRC

• Difficult to en-bloc resect for large lesions
Disadvantage of piecemeal resection

Piecemeal resection


                 is difficult to evaluate the
                  histological curability.

                 has a risk of local
                  recurrence tumor.
Local recurrence after EMR



                             National cancer center East, Japan
                             Katada et al. GIE 2005;61:219-25

116 consecutive patients with a total of 165
 squamous-cell carcinom
Retrospective study
Local recurrence: cancer was detected at the site
 of the EMR scar

Median follow-up: 35 months (12-110 months)
Method of EMR: 157 strip biopsy, 8 EEMR tube
Local recurrence rate: 20% (33/165 lesions)
Predictors of local recurrence after EMR
                     ~Univariate analysis~
                                   No.   Local rec (%)     p Value

Tumor size          <20             88      13 (14.8)
(mm)                                                         0.07
                    ≧20             77      20 (26.0)
Tumor location      Upper           22         1 (4.5)
                                                             0.03
                    Middle+lower   143      32 (22.4)
Depth of invasion m1+m2            128      23 (18.0)
                                                             0.2
                    m3              37      10 (27.0)
No.resection        en-bloc         38         1 (2.6)
                                                           <0.001
                    Piece meal     127      32 (25.2)
Multiple LVLs       Without         78      13 (16.7)
                                                            <0.01
                    With            38      15 (39.5)
LVL: Lugol-voiding lesion           Katada et al. GIE 2005;61:219-25
Predictors of local recurrence after EMR
       ~Multivariate logistic regression analysis~

Variables                           Odds ratio (95% CI)    p Value

Tumor size (≧20mm vs. <20mm)               1.2 (0.5-2.8)     0.7

Tumor location (Middle+lower vs. Upper) 3.1 (0.4-26.2)       0.2

Depth of invasion (m3 vs. m1+m2)           1.5 (0.6-3.8)     0.3

No. resection (piecemeal vs. en-bloc)     8.4 (1.0-69.7)     0.01

Multiple LVLs (with vs. without)           3.1 (1.1-8.5)     0.03




                                    Katada et al. GIE 2005;61:219-25
For reducing the local recurrence

 En-bloc resection seems to be the ideal for
reducing the local recurrence rate.

 However en-bloc resection is technically
difficult for larger lesions by conventional EMR.




                     ESD
  (Endoscopic Submucosal Dissection)
ESD for early gastric cancer
ESD One-Piece Resection Rate
                                    NCCH, 2000-2003

             Upper (n=176)         97% (170)
  Location   Middle (n=431)        97% (418)
             Lower (n=426)         98% (419)

             ≦ 20 (n=719)          98% (706)
  Size, mm   21-30 (n=176)         97% (171)
              >30 (n=138)          95% (131)

  Ulcer        +    (n=243)        97% (236)
               -    (n=790)        98% (772)

  Total             (n=1,033)      98% (1,008)

                   Oda I, et al. Digestive Endoscopy 2005
ESD in the esophagus
ESD procedures



 Marking

 Injection

 Initial incision

 Mucosal incision

 Submucosal dissection
Marking     Needle knife or Dual knife
   anal




   lesion




               FORCED COAG; 20W
   onal
Initial incision Needle knife or Dual knife
     anal




    lesion




     onal
                  ENDO CUT; 80W, Effect 3
Mucosal incision   IT knife 2 or Dual knife
   anal




   lesion




   onal
              ENDO CUT; 80W, Effect 3
Submucosal dissection   IT knife 2 or Dual knife

   anal




   lesion




   onal
                ENDO CUT; 80W, Effect 3
Mucosal inicision   IT knife 2 or Dual knife
   anal




   lesion




   onal
              ENDO CUT; 80W, Effect 3
Submucosal dissection   IT knife 2 or Dual knife

   anal




   lesion




   onal
                ENDO CUT; 80W, Effect 3
ESD (Video)
Results of esophageal ESD




              Ono S, et al. Gastroint Endosc 2009
Our series: EMR vs ESD for Lesions >2cm

                      EMR   (88)   ESD    (44)         P


One-piece resection   22 (25)      41 (93)         0.0001

Curative resection
(EP-LPM/ly-/v-/ce-)   13 (15)      15 (34)           0.01


Local recurrence       2 (2)         0 (0)            NS

                                   (); % NS; not significant
Perforation during Esophageal ESD
Subcutaneous & Mediastinal Emphysema
Induced by Perforation during Esophageal ESD




    Air insufflation        CO2 insufflation
                         Nonaka S, Oda I, et al, Surg Endosc 2010
Conclusions



 Noninvasive SCCs (m1) and intramucosal
  invasive SCCs limited to the lamina propria
  mucosae (m2) are definite indications for
  endoscopic resection with curative intent.

 ESD has an advantage for archiving en-bloc
  resection of large superficial esophageal SCC.

Más contenido relacionado

La actualidad más candente

The best way to treat locally advanced rectal cancer
The best way to treat locally advanced rectal cancerThe best way to treat locally advanced rectal cancer
The best way to treat locally advanced rectal cancerMohamed Abdulla
 
Management of locally advanced rectal cancer
Management of locally advanced rectal cancerManagement of locally advanced rectal cancer
Management of locally advanced rectal cancerDr. Abani Kanta Nanda
 
Il trattamento chirurgico del colangiocarcinoma - Gastrolearning®
Il trattamento chirurgico del colangiocarcinoma - Gastrolearning®Il trattamento chirurgico del colangiocarcinoma - Gastrolearning®
Il trattamento chirurgico del colangiocarcinoma - Gastrolearning®Gastrolearning
 
Pancreatic Neuroendocrine Tumors
Pancreatic Neuroendocrine TumorsPancreatic Neuroendocrine Tumors
Pancreatic Neuroendocrine TumorsJunish Bagga
 
Colorectal liver metastasis
Colorectal liver metastasisColorectal liver metastasis
Colorectal liver metastasismanish2189
 
Neoadjuvant therapy in colorectal carcinoma
Neoadjuvant therapy in colorectal carcinomaNeoadjuvant therapy in colorectal carcinoma
Neoadjuvant therapy in colorectal carcinomaAnkita Singh
 
Oligometastatic prostate cancer- radiation Therapy
Oligometastatic prostate cancer- radiation TherapyOligometastatic prostate cancer- radiation Therapy
Oligometastatic prostate cancer- radiation Therapykamali purushothaman
 
Management of hcc sneha
Management of hcc snehaManagement of hcc sneha
Management of hcc snehaSneha George
 
CARCINOMA RECTUM MANAGEMENT
CARCINOMA RECTUM MANAGEMENTCARCINOMA RECTUM MANAGEMENT
CARCINOMA RECTUM MANAGEMENTNabeel Yahiya
 
Approach to liver nodules.pptx
Approach to liver nodules.pptxApproach to liver nodules.pptx
Approach to liver nodules.pptxRebilHeiru2
 
RECTUM CANCER MANAGEMENT
RECTUM CANCER MANAGEMENTRECTUM CANCER MANAGEMENT
RECTUM CANCER MANAGEMENTKanhu Charan
 
Management Of Testicular Tumours
Management Of Testicular TumoursManagement Of Testicular Tumours
Management Of Testicular Tumoursfondas vakalis
 
SURGICAL EXPLORATION OF THE COMMON BILE DUCT.pptx
SURGICAL EXPLORATION OF THE COMMON BILE DUCT.pptxSURGICAL EXPLORATION OF THE COMMON BILE DUCT.pptx
SURGICAL EXPLORATION OF THE COMMON BILE DUCT.pptxmasoom parwez
 
Carcinoma rectum the complete aproach to how to investigate and treat a case ...
Carcinoma rectum the complete aproach to how to investigate and treat a case ...Carcinoma rectum the complete aproach to how to investigate and treat a case ...
Carcinoma rectum the complete aproach to how to investigate and treat a case ...nikhilameerchetty
 
Pancreatic neuroendocrine tumors
Pancreatic neuroendocrine tumors Pancreatic neuroendocrine tumors
Pancreatic neuroendocrine tumors suhas k r
 
Common Bile Duct Stones: Leave Them Get Them or Refer Them
Common Bile Duct Stones: Leave Them Get Them or Refer ThemCommon Bile Duct Stones: Leave Them Get Them or Refer Them
Common Bile Duct Stones: Leave Them Get Them or Refer ThemGeorge S. Ferzli
 

La actualidad más candente (20)

TNT MAYO.pptx
TNT MAYO.pptxTNT MAYO.pptx
TNT MAYO.pptx
 
The best way to treat locally advanced rectal cancer
The best way to treat locally advanced rectal cancerThe best way to treat locally advanced rectal cancer
The best way to treat locally advanced rectal cancer
 
Neuroendocrine tumors of pancreas
Neuroendocrine tumors of pancreasNeuroendocrine tumors of pancreas
Neuroendocrine tumors of pancreas
 
Management of locally advanced rectal cancer
Management of locally advanced rectal cancerManagement of locally advanced rectal cancer
Management of locally advanced rectal cancer
 
Il trattamento chirurgico del colangiocarcinoma - Gastrolearning®
Il trattamento chirurgico del colangiocarcinoma - Gastrolearning®Il trattamento chirurgico del colangiocarcinoma - Gastrolearning®
Il trattamento chirurgico del colangiocarcinoma - Gastrolearning®
 
Pancreatic Neuroendocrine Tumors
Pancreatic Neuroendocrine TumorsPancreatic Neuroendocrine Tumors
Pancreatic Neuroendocrine Tumors
 
Colorectal liver metastasis
Colorectal liver metastasisColorectal liver metastasis
Colorectal liver metastasis
 
Neoadjuvant therapy in colorectal carcinoma
Neoadjuvant therapy in colorectal carcinomaNeoadjuvant therapy in colorectal carcinoma
Neoadjuvant therapy in colorectal carcinoma
 
Oligometastatic prostate cancer- radiation Therapy
Oligometastatic prostate cancer- radiation TherapyOligometastatic prostate cancer- radiation Therapy
Oligometastatic prostate cancer- radiation Therapy
 
Management of hcc sneha
Management of hcc snehaManagement of hcc sneha
Management of hcc sneha
 
CARCINOMA RECTUM MANAGEMENT
CARCINOMA RECTUM MANAGEMENTCARCINOMA RECTUM MANAGEMENT
CARCINOMA RECTUM MANAGEMENT
 
Approach to liver nodules.pptx
Approach to liver nodules.pptxApproach to liver nodules.pptx
Approach to liver nodules.pptx
 
RECTUM CANCER MANAGEMENT
RECTUM CANCER MANAGEMENTRECTUM CANCER MANAGEMENT
RECTUM CANCER MANAGEMENT
 
RT in Ca Esophagus
RT in Ca EsophagusRT in Ca Esophagus
RT in Ca Esophagus
 
Management Of Testicular Tumours
Management Of Testicular TumoursManagement Of Testicular Tumours
Management Of Testicular Tumours
 
SURGICAL EXPLORATION OF THE COMMON BILE DUCT.pptx
SURGICAL EXPLORATION OF THE COMMON BILE DUCT.pptxSURGICAL EXPLORATION OF THE COMMON BILE DUCT.pptx
SURGICAL EXPLORATION OF THE COMMON BILE DUCT.pptx
 
Carcinoma rectum the complete aproach to how to investigate and treat a case ...
Carcinoma rectum the complete aproach to how to investigate and treat a case ...Carcinoma rectum the complete aproach to how to investigate and treat a case ...
Carcinoma rectum the complete aproach to how to investigate and treat a case ...
 
Pancreatic neuroendocrine tumors
Pancreatic neuroendocrine tumors Pancreatic neuroendocrine tumors
Pancreatic neuroendocrine tumors
 
Common Bile Duct Stones: Leave Them Get Them or Refer Them
Common Bile Duct Stones: Leave Them Get Them or Refer ThemCommon Bile Duct Stones: Leave Them Get Them or Refer Them
Common Bile Duct Stones: Leave Them Get Them or Refer Them
 
The Gist of GIST
The Gist of GISTThe Gist of GIST
The Gist of GIST
 

Similar a Endoscopy in Gastrointestinal Oncology - Slide 4 - I. Oda - Esophageal ESD

Endoscopy in Gastrointestinal Oncology - Slide 18 - T. Matsuda - Colorectal ESD
Endoscopy in Gastrointestinal Oncology - Slide 18 - T. Matsuda - Colorectal ESD Endoscopy in Gastrointestinal Oncology - Slide 18 - T. Matsuda - Colorectal ESD
Endoscopy in Gastrointestinal Oncology - Slide 18 - T. Matsuda - Colorectal ESD European School of Oncology
 
Can we apply the same indications of ESD for primary gastric cancer to remnan...
Can we apply the same indications of ESD for primary gastric cancer to remnan...Can we apply the same indications of ESD for primary gastric cancer to remnan...
Can we apply the same indications of ESD for primary gastric cancer to remnan...Saeed Al-Shomimi
 
Preoperative Radiotherapy In Extremity Soft Tissue Sarcoma
Preoperative Radiotherapy In Extremity Soft Tissue SarcomaPreoperative Radiotherapy In Extremity Soft Tissue Sarcoma
Preoperative Radiotherapy In Extremity Soft Tissue Sarcomafondas vakalis
 
Surgery of Rectal Cancer : Potentials and Limitations - Dimitris P. Korkolis
Surgery of Rectal Cancer : Potentials and Limitations - Dimitris P. KorkolisSurgery of Rectal Cancer : Potentials and Limitations - Dimitris P. Korkolis
Surgery of Rectal Cancer : Potentials and Limitations - Dimitris P. KorkolisDimitris P. Korkolis
 
Kupelian 2nd talk prostate igrt hyderabad 2013 (kupelian)
Kupelian 2nd talk prostate igrt hyderabad 2013 (kupelian)Kupelian 2nd talk prostate igrt hyderabad 2013 (kupelian)
Kupelian 2nd talk prostate igrt hyderabad 2013 (kupelian)Dr. Vijay Anand P. Reddy
 
Seed implantation for other body sites
Seed implantation for other body sitesSeed implantation for other body sites
Seed implantation for other body sitesAlfredo Polo
 
IGRT &amp; IMRT In Head Neck Cancer
IGRT &amp; IMRT In Head Neck CancerIGRT &amp; IMRT In Head Neck Cancer
IGRT &amp; IMRT In Head Neck CancerSapna Nangia
 
SRS-ROSE CASE FOR PITUITARY ADENOMA
SRS-ROSE CASE FOR PITUITARY ADENOMASRS-ROSE CASE FOR PITUITARY ADENOMA
SRS-ROSE CASE FOR PITUITARY ADENOMAKanhu Charan
 
Impact of previous stenting on the outcome of (2)
Impact of previous stenting on the outcome of (2)Impact of previous stenting on the outcome of (2)
Impact of previous stenting on the outcome of (2)escts2012
 
Larynx Preservation: the Nonsurgical Approach by Jan B. Vermorken
Larynx Preservation: the Nonsurgical Approach by Jan B. VermorkenLarynx Preservation: the Nonsurgical Approach by Jan B. Vermorken
Larynx Preservation: the Nonsurgical Approach by Jan B. VermorkenEurasian Federation of Oncology
 

Similar a Endoscopy in Gastrointestinal Oncology - Slide 4 - I. Oda - Esophageal ESD (20)

Endoscopy in Gastrointestinal Oncology - Slide 18 - T. Matsuda - Colorectal ESD
Endoscopy in Gastrointestinal Oncology - Slide 18 - T. Matsuda - Colorectal ESD Endoscopy in Gastrointestinal Oncology - Slide 18 - T. Matsuda - Colorectal ESD
Endoscopy in Gastrointestinal Oncology - Slide 18 - T. Matsuda - Colorectal ESD
 
Can we apply the same indications of ESD for primary gastric cancer to remnan...
Can we apply the same indications of ESD for primary gastric cancer to remnan...Can we apply the same indications of ESD for primary gastric cancer to remnan...
Can we apply the same indications of ESD for primary gastric cancer to remnan...
 
Ewing sarcoma
Ewing sarcomaEwing sarcoma
Ewing sarcoma
 
Preoperative Radiotherapy In Extremity Soft Tissue Sarcoma
Preoperative Radiotherapy In Extremity Soft Tissue SarcomaPreoperative Radiotherapy In Extremity Soft Tissue Sarcoma
Preoperative Radiotherapy In Extremity Soft Tissue Sarcoma
 
MON 2011 - Slide 22 - W. Weder - Surgery
MON 2011 - Slide 22 - W. Weder - SurgeryMON 2011 - Slide 22 - W. Weder - Surgery
MON 2011 - Slide 22 - W. Weder - Surgery
 
Veronesispeech-IORT
Veronesispeech-IORTVeronesispeech-IORT
Veronesispeech-IORT
 
MCC 2011 - Slide 28
MCC 2011 - Slide 28MCC 2011 - Slide 28
MCC 2011 - Slide 28
 
Surgery of Rectal Cancer : Potentials and Limitations - Dimitris P. Korkolis
Surgery of Rectal Cancer : Potentials and Limitations - Dimitris P. KorkolisSurgery of Rectal Cancer : Potentials and Limitations - Dimitris P. Korkolis
Surgery of Rectal Cancer : Potentials and Limitations - Dimitris P. Korkolis
 
Ewings sarcoma - Dr. Vandana
Ewings sarcoma - Dr. VandanaEwings sarcoma - Dr. Vandana
Ewings sarcoma - Dr. Vandana
 
Kupelian 2nd talk prostate igrt hyderabad 2013 (kupelian)
Kupelian 2nd talk prostate igrt hyderabad 2013 (kupelian)Kupelian 2nd talk prostate igrt hyderabad 2013 (kupelian)
Kupelian 2nd talk prostate igrt hyderabad 2013 (kupelian)
 
Trauma surgery audit 2016
Trauma surgery audit 2016Trauma surgery audit 2016
Trauma surgery audit 2016
 
Seed implantation for other body sites
Seed implantation for other body sitesSeed implantation for other body sites
Seed implantation for other body sites
 
IGRT &amp; IMRT In Head Neck Cancer
IGRT &amp; IMRT In Head Neck CancerIGRT &amp; IMRT In Head Neck Cancer
IGRT &amp; IMRT In Head Neck Cancer
 
SRS-ROSE CASE FOR PITUITARY ADENOMA
SRS-ROSE CASE FOR PITUITARY ADENOMASRS-ROSE CASE FOR PITUITARY ADENOMA
SRS-ROSE CASE FOR PITUITARY ADENOMA
 
Tuberculosis And Airborne
Tuberculosis And AirborneTuberculosis And Airborne
Tuberculosis And Airborne
 
Crohn's disase
Crohn's disaseCrohn's disase
Crohn's disase
 
Impact of previous stenting on the outcome of (2)
Impact of previous stenting on the outcome of (2)Impact of previous stenting on the outcome of (2)
Impact of previous stenting on the outcome of (2)
 
Rectal cancer
Rectal cancerRectal cancer
Rectal cancer
 
Larynx Preservation: the Nonsurgical Approach by Jan B. Vermorken
Larynx Preservation: the Nonsurgical Approach by Jan B. VermorkenLarynx Preservation: the Nonsurgical Approach by Jan B. Vermorken
Larynx Preservation: the Nonsurgical Approach by Jan B. Vermorken
 
44951
4495144951
44951
 

Más de European School of Oncology

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...European School of Oncology
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...European School of Oncology
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasEuropean School of Oncology
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasEuropean School of Oncology
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineEuropean School of Oncology
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...European School of Oncology
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artEuropean School of Oncology
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...European School of Oncology
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer European School of Oncology
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerEuropean School of Oncology
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artEuropean School of Oncology
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...European School of Oncology
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artEuropean School of Oncology
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...European School of Oncology
 

Más de European School of Oncology (20)

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
W. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - GuidelinesW. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - Guidelines
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomas
 
H. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the artH. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the art
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
 
1 azim
1 azim1 azim
1 azim
 
H. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the artH. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the art
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccine
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the art
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
 
V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancer
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the art
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the art
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
 

Endoscopy in Gastrointestinal Oncology - Slide 4 - I. Oda - Esophageal ESD

  • 1. Esophageal ESD National Cancer Center Hospital, Tokyo Endoscopy Division Ichiro Oda, MD
  • 2. Agenda  Introduction  Indication of Endoscopic resection for esophageal SCC  ESD for esophageal SCC
  • 3. Incidence and Mortality Esophageal cancer  It is the eighth most common cancer worldwide, accounting for 462,000 new cases in 2002.  It is the sixth most common cause of cancer related death (386,000 deaths).  Squamous cell carcinoma (SCC) is the most common histological type worldwide. Japan Adenocarcinoma 1-2% SCC 92-93% Others 5-6% Muto M, et al. J Clin Oncol 2010;28:1566-72.
  • 4. Risk Factors for SCC in Esophagus  Alcohol  Smoking  Male  over 50ys  History of Esophageal Cancer  History of Head and Neck Cancer  Family history  Achalasia Castellsague X, et al , Cancer 82:657-664,1999 Aggestrup S, et al. Chest 102:1013‐ 1016,1992 T. Yoshida , et al. The GI Forefront (Japanese Journal) vol3 (2) 118-122,2007
  • 5. Risk Factors for SCC in Esophagus  Prevalence of drinkers and smokers in Japanese men is so high.  35.7% of men drink every day  43.3% are current smokers in 2004  Aldehyde dehydrogenase-2 (ALDH2) genotype determines an individual’s blood acetaldehyde concentration.  Acetaldehyde has been established as a carcinogen in experimental animals and is also suspected of playing a critical role in cancer development in humans. Yokoyama T, et al. Cancer Epidemiol Biomarkers Prev 2008;17:2846-54.
  • 6. Risk Factors for SCC in Esophagus  Recent study shows that inactive ALDH2 is a very strong risk factor for esophageal SCC in alcohol drinkers.  Alcohol flushing is a marker of inactive ALDH2. Yokoyama T, et al. Cancer Epidemiol Biomarkers Prev 2008;17:2846-54.
  • 7. Agenda  Introduction  Indication of Endoscopic resection for esophageal SCC ESD for esophageal SCC
  • 8. Indications for endosopic resection  Depth of tumor invasion  Mucosal defect (luminal circumference)
  • 9. Relationship Between Depth of Invasion and Lymph Node Metastasis in Superficial Esophageal Cancer m1 m2 m3 sm1 sm2 sm3 EP LPM MM SM Frequency of Lymph Node Metastasis 0% 0% 10〜15% 40〜50% Definite Indication Relative Indication Definite Non-indication
  • 10. M2
  • 11. SM2
  • 12. Mucosal defect >3/4 luminal circumference Require balloon dilatation Mucosal defect >3/4 luminal circumference develop stenosis
  • 13. Stenosis Stenosis +ve Stenosis -ve n=11 n=54 < 1/2 2 40 Circumferental > 1/2 4 13 extention > 3/4 5 1 < 0.0001 Longitudinal diameter (mm) 45.0±15.9 31.5±13.6 0.0062 Circumferental diameter (mm) 37.2±8.6 26.8±9.7 0.0020 Ono S, Fujishiro M, et al. Gastroint Endosc 2009
  • 14. Agenda  Introduction  Indication of Endoscopic resection for esophageal SCC ESD for esophageal SCC
  • 15. Endoscopic resection modalities  Endoscopic mucosal resection (EMR)  Strip biopsy  EMR with cap  EMR with ligating device  EEMR tube  etc  Endoscopic submucosal dissection (ESD)
  • 16. EMR Strip Biopsy EMR with a cap-fitted scope (EMRC) Tada M, et al. Endoscopy 1993 Inoue H et al. Gastrointest Endosc. 1993 • Technically simple • Low en-bloc resection rate • Difficult to resect large lesions
  • 17. EMRC SCC, m1, , 1cm, ly0, v0, cut end(-)
  • 18. Piecemeal resection of EMRC • Difficult to en-bloc resect for large lesions
  • 19. Disadvantage of piecemeal resection Piecemeal resection  is difficult to evaluate the histological curability.  has a risk of local recurrence tumor.
  • 20. Local recurrence after EMR National cancer center East, Japan Katada et al. GIE 2005;61:219-25 116 consecutive patients with a total of 165 squamous-cell carcinom Retrospective study Local recurrence: cancer was detected at the site of the EMR scar Median follow-up: 35 months (12-110 months) Method of EMR: 157 strip biopsy, 8 EEMR tube Local recurrence rate: 20% (33/165 lesions)
  • 21. Predictors of local recurrence after EMR ~Univariate analysis~ No. Local rec (%) p Value Tumor size <20 88 13 (14.8) (mm) 0.07 ≧20 77 20 (26.0) Tumor location Upper 22 1 (4.5) 0.03 Middle+lower 143 32 (22.4) Depth of invasion m1+m2 128 23 (18.0) 0.2 m3 37 10 (27.0) No.resection en-bloc 38 1 (2.6) <0.001 Piece meal 127 32 (25.2) Multiple LVLs Without 78 13 (16.7) <0.01 With 38 15 (39.5) LVL: Lugol-voiding lesion Katada et al. GIE 2005;61:219-25
  • 22. Predictors of local recurrence after EMR ~Multivariate logistic regression analysis~ Variables Odds ratio (95% CI) p Value Tumor size (≧20mm vs. <20mm) 1.2 (0.5-2.8) 0.7 Tumor location (Middle+lower vs. Upper) 3.1 (0.4-26.2) 0.2 Depth of invasion (m3 vs. m1+m2) 1.5 (0.6-3.8) 0.3 No. resection (piecemeal vs. en-bloc) 8.4 (1.0-69.7) 0.01 Multiple LVLs (with vs. without) 3.1 (1.1-8.5) 0.03 Katada et al. GIE 2005;61:219-25
  • 23. For reducing the local recurrence  En-bloc resection seems to be the ideal for reducing the local recurrence rate.  However en-bloc resection is technically difficult for larger lesions by conventional EMR. ESD (Endoscopic Submucosal Dissection)
  • 24. ESD for early gastric cancer
  • 25. ESD One-Piece Resection Rate NCCH, 2000-2003 Upper (n=176) 97% (170) Location Middle (n=431) 97% (418) Lower (n=426) 98% (419) ≦ 20 (n=719) 98% (706) Size, mm 21-30 (n=176) 97% (171) >30 (n=138) 95% (131) Ulcer + (n=243) 97% (236) - (n=790) 98% (772) Total (n=1,033) 98% (1,008) Oda I, et al. Digestive Endoscopy 2005
  • 26. ESD in the esophagus
  • 27. ESD procedures  Marking  Injection  Initial incision  Mucosal incision  Submucosal dissection
  • 28. Marking Needle knife or Dual knife anal lesion FORCED COAG; 20W onal
  • 29. Initial incision Needle knife or Dual knife anal lesion onal ENDO CUT; 80W, Effect 3
  • 30. Mucosal incision IT knife 2 or Dual knife anal lesion onal ENDO CUT; 80W, Effect 3
  • 31. Submucosal dissection IT knife 2 or Dual knife anal lesion onal ENDO CUT; 80W, Effect 3
  • 32. Mucosal inicision IT knife 2 or Dual knife anal lesion onal ENDO CUT; 80W, Effect 3
  • 33. Submucosal dissection IT knife 2 or Dual knife anal lesion onal ENDO CUT; 80W, Effect 3
  • 35. Results of esophageal ESD Ono S, et al. Gastroint Endosc 2009
  • 36. Our series: EMR vs ESD for Lesions >2cm EMR (88) ESD (44) P One-piece resection 22 (25) 41 (93) 0.0001 Curative resection (EP-LPM/ly-/v-/ce-) 13 (15) 15 (34) 0.01 Local recurrence 2 (2) 0 (0) NS (); % NS; not significant
  • 38. Subcutaneous & Mediastinal Emphysema Induced by Perforation during Esophageal ESD Air insufflation CO2 insufflation Nonaka S, Oda I, et al, Surg Endosc 2010
  • 39. Conclusions  Noninvasive SCCs (m1) and intramucosal invasive SCCs limited to the lamina propria mucosae (m2) are definite indications for endoscopic resection with curative intent.  ESD has an advantage for archiving en-bloc resection of large superficial esophageal SCC.